Literature DB >> 27421717

Guillain-Barré syndrome in Colombia: where do we stand now?

María P Mahecha1, Ernesto Ojeda2, Daniel A Vega3, Juan C Sarmiento-Monroy1, Juan-Manuel Anaya4.   

Abstract

Guillain-Barré syndrome (GBS) is a rapid-onset muscle weakness disease caused by the immune-mediated damage of the peripheral nervous system. Since there is an increase incidence of GBS cases in Latin America, particularly in Colombia, and most of them are currently preceded by Zika virus (ZIKV) infection, we aimed to assess the available evidence of the disease in Colombia through a systematic literature review. Out of 51 screened abstracts, only 16 corresponded to articles that met inclusion criteria, of which 15 were case reports or case series. A total of 796 cases of GBS were reported in the included articles. The majority of patients were males (66.8 %) and younger than 50 years old (94 %). An infectious disease before the onset of GBS was registered in 31 % of patients, with gastrointestinal or respiratory symptoms being the most frequently observed. In those cases in which electrodiagnostic tests were performed, the most common subphenotype was acute inflammatory demyelinating polyneuropathy (17 %). Death was reported in 15 % of patients. Data regarding GBS in Colombia is scant and heterogeneous. Taking into account the burden of the disease and the recent rise of GBS cases associated with ZIKV, a careful patient evaluation and a systematic collection of data are warranted. A form to data gathering is proposed.

Entities:  

Keywords:  Anti-gangliosides antibodies; Guillain–Barré syndrome; Latin America; Zika virus

Mesh:

Year:  2017        PMID: 27421717     DOI: 10.1007/s12026-016-8816-8

Source DB:  PubMed          Journal:  Immunol Res        ISSN: 0257-277X            Impact factor:   2.829


  50 in total

Review 1.  The epidemiology of Guillain-Barré syndrome worldwide. A systematic literature review.

Authors:  Anita McGrogan; Gemma C Madle; Helen E Seaman; Corinne S de Vries
Journal:  Neuroepidemiology       Date:  2008-12-17       Impact factor: 3.282

2.  An outbreak of acute polyradiculoneuropathy in Columbia in 1968.

Authors:  F Lopez; J H Lopez; H Holguin; T H Flewett
Journal:  Am J Epidemiol       Date:  1973-09       Impact factor: 4.897

3.  [Clinical features of Guillain-Barré syndrome in 41 patients admitted to a public hospital].

Authors:  Gabriel Cea; Paula Jara; Fernando Quevedo
Journal:  Rev Med Chil       Date:  2015-02       Impact factor: 0.553

4.  Clinical characteristics of Guillain-Barré syndrome in a tropical country: a Brazilian experience.

Authors:  M E Dourado; R H Félix; W K A da Silva; J W Queiroz; S M B Jeronimo
Journal:  Acta Neurol Scand       Date:  2011-03-24       Impact factor: 3.209

5.  Motor recovery after Guillain-Barré syndrome in childhood.

Authors:  Fernando Ortiz-Corredor; Marta Peña-Preciado; Jorge Díaz-Ruíz
Journal:  Disabil Rehabil       Date:  2007 Jun 15-30       Impact factor: 3.033

Review 6.  Peripheral nerve proteins as potential autoantigens in acute and chronic inflammatory demyelinating polyneuropathies.

Authors:  Jia Pei Lim; Jérôme Devaux; Nobuhiro Yuki
Journal:  Autoimmun Rev       Date:  2014-08-27       Impact factor: 9.754

Review 7.  Guillain-Barré syndrome: causes, immunopathogenic mechanisms and treatment.

Authors:  Anil K Jasti; Carlo Selmi; Juan C Sarmiento-Monroy; Daniel A Vega; Juan-Manuel Anaya; M Eric Gershwin
Journal:  Expert Rev Clin Immunol       Date:  2016-06-21       Impact factor: 4.473

8.  Zika virus infection complicated by Guillain-Barre syndrome--case report, French Polynesia, December 2013.

Authors:  E Oehler; L Watrin; P Larre; I Leparc-Goffart; S Lastere; F Valour; L Baudouin; Hp Mallet; D Musso; F Ghawche
Journal:  Euro Surveill       Date:  2014-03-06

9.  Guillain-Barré syndrome and influenza virus infection.

Authors:  Valérie Sivadon-Tardy; David Orlikowski; Raphaël Porcher; Tarek Sharshar; Marie-Christine Durand; Vincent Enouf; Flore Rozenberg; Christiane Caudie; Djillali Annane; Sylvie van der Werf; Pierre Lebon; Jean-Claude Raphaël; Jean-Louis Gaillard; Elyanne Gault
Journal:  Clin Infect Dis       Date:  2009-01-01       Impact factor: 9.079

10.  Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barré syndrome.

Authors:  Jeffrey L Winters; David Brown; Elisabeth Hazard; Ashok Chainani; Chester Andrzejewski
Journal:  BMC Health Serv Res       Date:  2011-05-16       Impact factor: 2.655

View more
  5 in total

Review 1.  Neuroimaging findings of postnatally acquired Zika virus infection: a pictorial essay.

Authors:  Mohammad Zare Mehrjardi; Guillaume Carteaux; Andrea Poretti; Morteza Sanei Taheri; Sonia Bermudez; Heron Werner; Luiz Celso Hygino da Cruz
Journal:  Jpn J Radiol       Date:  2017-04-26       Impact factor: 2.374

2.  Role of environmental factors in autoimmunity: pearls from the 10th international Congress on autoimmunity, Leipzig, Germany 2016.

Authors:  Carlo Perricone; Guido Valesini
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

3.  Increased Hospitalizations for Neuropathies as Indicators of Zika Virus Infection, according to Health Information System Data, Brazil.

Authors:  Christovam Barcellos; Diego Ricardo Xavier; Ana Luiza Pavão; Cristiano Siqueira Boccolini; Maria Fatima Pina; Marcel Pedroso; Dalia Romero; Anselmo Rocha Romão
Journal:  Emerg Infect Dis       Date:  2016-11-15       Impact factor: 6.883

4.  Long-term outcomes of Guillain-Barré syndrome possibly associated with Zika virus infection.

Authors:  Diana M Walteros; Jesus Soares; Ashley R Styczynski; Joseph Y Abrams; Jose I Galindo-Buitrago; Jorge Acosta-Reyes; Elsa Bravo-Ribero; Zuleima E Arteta; Alma Solano-Sanchez; Franklyn E Prieto; Maritza Gonzalez-Duarte; Edgar Navarro-Lechuga; Jorge L Salinas; Ermias D Belay; Lawrence B Schonberger; Inger K Damon; Martha L Ospina; James J Sejvar
Journal:  PLoS One       Date:  2019-08-01       Impact factor: 3.240

Review 5.  Autoimmune Neurological Conditions Associated With Zika Virus Infection.

Authors:  Yeny Acosta-Ampudia; Diana M Monsalve; Luis F Castillo-Medina; Yhojan Rodríguez; Yovana Pacheco; Susan Halstead; Hugh J Willison; Juan-Manuel Anaya; Carolina Ramírez-Santana
Journal:  Front Mol Neurosci       Date:  2018-04-11       Impact factor: 5.639

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.